Investors in CureVac N.V. CVAC need to pay close attention to the stock based on moves in the options market lately. That is because the Dec 20, 2024 $06.00 Call had some of the highest implied volatility...
Issued on behalf of BioVaxys Technology Corp. VANCOUVER – USA News Group – Back in 2022, Nature published...
First patient administered in dose-confirmation Part B of Phase 1 study with mRNA-based, multiepitope cancer vaccine candidate CVGBM
GSK acquires full rights to develop, manufacture and commercialize globally mRNA candidate vaccines for influenza and COVID-19, including combinations
A German court temporarily suspended proceedings in CureVac's IP lawsuit against BioNTech.
The cold and flu season is upon us, but COVID-19 cases and hospitalizations have also increased recently. The Centers for Disease Control (CDC) will be voting
The company, which focuses on mRNA therapies, began a phase 1 trial for its cancer vaccine candidate.
The war on cancer advances with the German company's latest clinical development.
March S&P 500 futures (ESH23) are trending down -0.41% this morning after three major U.S. benchmark indices ended the regular session lower as weak economic data and hawkish comments from Federal Reserve...
The stock rose for the third consecutive day.